Oncotherapeutics Hires Hilda Chamras, Ph. D as Director of Clinical Operations
In her role with Oncotherapeutics, Dr. Chamras will run all clinical operations for the company and manage key roles including Manager of Clinical Operations and several project managers, CRA’s, medical writers and biostaticians.
West Hollywood, CA (I-Newswire) November 12, 2012 - Oncotherapeutics, an oncology specific CRO has added Hilda Chamras, Ph. D as its new Director of Clinical Operations. Most recently Dr. Chamras was Director, Clinical Operations at ALUMINAID Inc. in Santa Monica and brings more than 10 years of oncology clinical research experience to Oncotherapeutics. Dr. Chamras replaces former Director of Clinical Operations, Erika Pelzer who will now serve in a consulting capacity.
Dr. Hilda Chamras holds a Ph.D., Biochemistry and a M.S., Biochemistry from the University of Paris (Pierre et Marie Curie), Paris, France. She started her research career at UCLA as a research scientist and transferred to Pacific Shores Medical Group.. She was then a medical liaison for Medtronic and a Senior Associate Medical Research Manager for AMGEN. For three years, Dr. Chamras was a consultant for the European Commission and MESR (Ministère de l'Enseignement Supérieur et de la Recherche-French Ministry of High Education and Research) in Paris, France. She then returned to UCLA in 2010 as a Project Manager for the California Institute of Regenerative Medicine (CIRM). In her most recent position at Aluminaid, Inc., Dr. Chamras directed and managed the clinical, R&D, manufacturing and regulatory team for the development, implementation and execution of all preclinical studies.
Chief Operating Officer of Oncotherapeutics, Geoffrey M. Gee, Esq., said, “We are delighted to welcome Dr. Chamras to Oncotherapeutics and know that her wealth of experience will be a great asset to us as we continue to grow”.
With team expertise in phase I-IV clinical trials and pharmacokinetic studies, Oncotherapeutics offers a wide array of services that are custom tailored to each trial. Nationally recognized research oncologists and key opinion leaders in the oncology field oversee senior level clinical research teams for every clinical trial. Oncotherapeutics has successfully conducted a multitude of oncology studies in the areas of multiple myeloma, myelodysplastic syndrome, monoclonal gammopathy of undetermined significance (MGUS), non-small cell lung cancer (NSCLC), advanced melanoma, studies on breakthrough cancer pain, other hematologic malignancies, and metastatic bone disease. For more information, please visit www.oncotherapeutics.com or call 310-623-1200 .
Cheryl A. Cross
9201 Sunset Blvd.,
Phone : 310-406-1035
Published in:Science and Research
Published On:November 12, 2012
Print Release:Print Release
If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the I-Newswire.com press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.
F1000Research Aims to Reduce Publication Bias
Phare Consulting Pushes For Comprehensive Growth In the Security Manufacturing Sector
Differentiated & Focused Conference On Polymeric Materials In Medical Devices Undefined. San Francisco, CA, USA, JUNE 26-28, 2013
Capital Resource Partners Purchases Gamma Medica’s Pre-Clinical Business to Form New Entity, Trifoil Imaging
Well Intervention Market Worth $17.48 Billion By 2018